Skip to content
value.today
PetMed Express, Inc. logo

PetMed Express, Inc.

PETS
$27 Mmarket cap on Oct 15, 2026-82.8% since Jan 2024
1M
-25.0%
Compare
World rank
#23,451
Revenue
$179 M
For year ending March-2026
Net income
$-57 M
-32.0% margin
SEC filing
Employees
212
As on 2022
value.today research

PetMed Express, Inc. in brief

PetMed Express, Inc. is a listed company in the Retail - Pharmacy industry, based in Delray Beach, Florida, USA. It was founded in 1996. Its market value was $27 M on 15 October 2026, which makes it the 23,451st largest listed company in the world and the 4,068th largest in the USA on this site. In the year to March 2026 it had sales of $179 M and a net loss of $57 M. It employs about 212 people and Jeffrey Allen Willard is its chief executive. Its largest business segments by sales in 2026 were Reportable (100%). Its shares trade under the symbol PETS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About PetMed Express, Inc.

PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

PetMed Express, Inc. timeline

4 events, 1996–2020
  1. 1996
  2. 🏁
    · approximate
    Founded
  3. 2000
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2018
  6. •
    Legal Entity Identifier issued
    LEI 529900PGHW5ASJ1AZL48 registered.
  7. 2020
  8. 💰
    Record revenue of $304 million
    FY2020, the highest of the 8 years on record.

Events of PetMed Express, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$176 M$353 M$529 M$705 M2020202120222023202420252026

World rank over time

▼ down 12,213 places since 2020
2020-01-01: #11252#11,25220202021-01-01: #9877#9,87720212022-01-07: #13202#13,20220222022-12-25: #14196#14,19620222023-07-30: #15818#15,81820232024-01-05: #19222#19,22220242026-03-08: #10806#10,80620262026-08-01: #20118#20,11820262026-09-22: #22562#22,56220262026-10-15: #23465#23,4652026

Rank in USA: #2,518 (Jan 2020) · #2,541 (Jan 2021) · #3,231 (Jan 2022) · #2,911 (Dec 2022) · #3,215 (Jul 2023) · #3,419 (Jan 2024) · #2,115 (Mar 2026) · #3,805 (Aug 2026) · #3,967 (Sep 2026) · #4,071 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.2×
Price / book
0.9×
Free cash flow yield
-123.7%
Net margin (TTM)
-17.0%
Operating margin
-32.8%
Return on equity
-94.0%
Liabilities / assets
64.4%
Revenue growth
-21.1%
Revenue per employee
$844 K
Profit per employee
$-270 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Mar 2019: revenue $283M, net income $38M$283MFY19Fiscal year ending Mar 2020: revenue $284M, net income $26M$284MFY20Fiscal year ending Mar 2021: revenue $304M, net income $24M$304MFY21Fiscal year ending Mar 2022: revenue $272M, net income $19M$272MFY22Fiscal year ending Mar 2023: revenue $248M, net income $5M$248MFY23Fiscal year ending Mar 2024: revenue $274M, net income $-7M$274MFY24Fiscal year ending Mar 2025: revenue $227M, net income $-6M$227MFY25Fiscal year ending Mar 2026: revenue $179M, net income $-57M$179MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Mar 2026$179M-21.1%$-59M$-57M-32.0%
Mar 2025$227M-17.2%$-2M$-6M-2.8%
Mar 2024$274M+10.7%$-8M$-7M-2.7%
Mar 2023$248M-9.1%$6M$5M2.1%
Mar 2022$272M-10.3%$24M$19M6.9%
Mar 2021$304M+6.8%$31M$24M7.9%
Mar 2020$284M+0.2%$31M$26M9.1%
Mar 2019$283M—$46M$38M13.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Mar 2026$-28M$5M$-33M$-2.74$0.00
Mar 2025$5M$5M$-0M$-0.30$0.00
Mar 2024$4M$5M$-0M$-0.37$0.60
Mar 2023$28M$5M$23M$0.25$1.20
Mar 2022$19M$2M$17M$0.92$1.20
Mar 2021$40M$2M$38M$1.19$1.12
Mar 2020$39M$2M$37M$1.29$1.08
Mar 2019$45M$1M$45M$1.84$1.06

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$160M
Net income, trailing 12 months
$-27M
RevenueNet income
Three months to Dec 2024: revenue $52M, net income $-1M$52MDec ’24Three months to Mar 2025 (from the annual report): revenue $51M, net income $-12M$51MMar ’25Three months to Jun 2025: revenue $51M, net income $-34M$51MJun ’25Three months to Sep 2025: revenue $44M, net income $-9M$44MSep ’25Three months to Dec 2025: revenue $41M, net income $-11M$41MDec ’25Three months to Mar 2026 (from the annual report): revenue $43M, net income $-4M$43MMar ’26Three months to Jun 2026: revenue $41M, net income $-6M$41MJun ’26Three months to Sep 2026: revenue $36M, net income $-6M$36MSep ’26

Latest quarter to Sep 2026: revenue $36M (-19.4% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of PetMed Express, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$179 M
Operating income
$-59 M
Net income
$-57 M

For year ending March-2026 · source: SEC filing

Balance sheet

Total assets
$81 M
Total liabilities
$52 M
Total equity
$29 M

As of March-2026

Top 48 institutional investors in PetMed Express, Inc.#

As of Sep 30, 2026
48 institutions held 4.6 M shares (about 20.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 16.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in PetMed Express, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Renaissance Technologies LLC1,070,630-60,600 (-5.36%)4.82%$1 MNov 12, 2026
2Vanguard Capital Management LLC827,3970 (0.00%)3.72%$1 MNov 13, 2026
3BlackRock, Inc.467,747-100,508 (-17.69%)2.10%$1 MNov 13, 2026
4Tudor Investment Corp Et Al251,604+170,197 (+209.07%)1.13%$0 MNov 16, 2026
5UMB Bank, n.a.235,000+175,000 (+291.67%)1.06%$0 MNov 6, 2026
6Steel Partners Holdings L.P.193,6640 (0.00%)0.87%$0 MNov 10, 2026
7Geode Capital Management, LLC175,665-28,410 (-13.92%)0.79%$0 MNov 6, 2026
8UBS Group AG169,196+30,866 (+22.31%)0.76%$0 MNov 10, 2026
9State Street Corp138,273+33,100 (+31.47%)0.62%$0 MNov 12, 2026
10Bridgeway Capital Management, LLC133,541+12,493 (+10.32%)0.60%$0 MNov 16, 2026
11Federated Hermes, Inc.131,196-80,974 (-38.16%)0.59%$0 MNov 12, 2026
12Price T Rowe Associates Inc /MD/129,9330 (0.00%)0.58%$0 MNov 16, 2026
13Vanguard Fiduciary Trust Co110,4810 (0.00%)0.50%$0 MNov 13, 2026
14Empowered Funds, LLC104,841+22,493 (+27.31%)0.47%$0 MNov 13, 2026
15Formidable Asset Management, LLC78,451-7,100 (-8.30%)0.35%$0 MNov 3, 2026
16Dimensional Fund Advisors LP60,3530 (0.00%)0.27%$0 MNov 4, 2026
17Rangeley Capital, LLC58,855-62,145 (-51.36%)0.26%$0 MNov 16, 2026
18Citadel Advisors LLC55,276-18,851 (-25.43%)0.25%$0 MNov 16, 2026
19Northern Trust Corp40,598-2,055 (-4.82%)0.18%$0 MNov 16, 2026
20Susquehanna International Group, LLP38,603-9,130 (-19.13%)0.17%$0 MNov 16, 2026
21XTX Topco Ltd27,630-14,303 (-34.11%)0.12%$0 MNov 16, 2026
22IMC-Chicago, LLC18,243-4,681 (-20.42%)0.08%$0 MNov 5, 2026
23Goldman Sachs Group Inc12,383New0.06%$0 MNov 16, 2026
24American Century Companies Inc12,266-605 (-4.70%)0.06%$0 MNov 12, 2026
25Simplex Trading, LLC12,122-12,723 (-51.21%)0.05%$0 MNov 4, 2026
Show all 48: investors 26 to 48
Institutional investors 26 to 48 in PetMed Express, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Morgan Stanley12,097+493 (+4.25%)0.05%$0 MNov 13, 2026
27Vanguard Global Advisers, LLC8,1200 (0.00%)0.04%$0 MNov 13, 2026
28Citigroup Inc3,450+3,441 (+38233.33%)0.02%$0 MNov 4, 2026
29Osaic Holdings, Inc.2,067-1,460 (-41.39%)0.01%$0 MNov 12, 2026
30Tower Research Capital LLC (TRC)1,372+1,204 (+716.67%)0.01%$0 MNov 16, 2026
31SBI Securities Co., Ltd.985-134 (-11.97%)0.00%$0 MOct 22, 2026
32Bank & Trust Co8230 (0.00%)0.00%$0 MOct 7, 2026
33Nuveen, LLC633New0.00%$0 MNov 10, 2026
34Harbour Investments, Inc.5400 (0.00%)0.00%$0 MNov 9, 2026
35Allworth Financial LP4940 (0.00%)0.00%$0 MNov 17, 2026
36Jones Financial Companies Lllp4150 (0.00%)0.00%$0 MNov 13, 2026
37Ascentis Independent Advisors3560 (0.00%)0.00%$0 MNov 3, 2026
38Wells Fargo & Company/mn3000 (0.00%)0.00%$0 MNov 16, 2026
39BNP Paribas Financial Markets291-8,895 (-96.83%)0.00%$0 MNov 12, 2026
40Rothschild Investment LLC2500 (0.00%)0.00%$0 MNov 10, 2026
41Farther Finance Advisors, LLC1510 (0.00%)0.00%$0 MOct 8, 2026
42FMR LLC104+44 (+73.33%)0.00%$0 MNov 10, 2026
43Elevated Capital Advisors, LLC500 (0.00%)0.00%$0 MNov 4, 2026
44Royal Bank Of Canada31+1 (+3.33%)0.00%$0 MNov 16, 2026
45Caitong International Asset Management Co., Ltd11-1 (-8.33%)0.00%$0 MOct 29, 2026
46Barclays PLC7New0.00%$0 MNov 6, 2026
47CoreCap Advisors, LLC40 (0.00%)0.00%$0 MOct 8, 2026
48Steward Partners Investment Advisory, LLC20 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding PetMed Express, Inc.#

27 funds hold shares worth $3 M (about 7.1% of the company). Since their previous reports 7 added shares and 19 sold, selling $2 M net.
Mutual funds holding PetMed Express, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.602,795$1 M2.7%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.211,088$0 M0.95%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC112,623$0 M0.51%<0.01%+11%May 31, 2026
🇺🇸 Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value FundFederated Hermes Equity Funds116,820$0 M0.53%0.13%no changeJun 30, 2026
🇺🇸 Federated Hermes MDT Small Cap Core ETFFederated Advisory Services Company75,863$0 M0.34%0.06%+56%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors82,722$0 M0.37%<0.01%+2.4%Jun 30, 2026
🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers82,348$0 M0.37%0.01%+9.8%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors51,552$0 M0.23%<0.01%+35%Jun 30, 2026
🇺🇸 T. Rowe Price Total Equity Market Index FundT. Rowe Price Associates, Inc.48,911$0 M0.22%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC35,726$0 M0.16%<0.01%no changeMay 31, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.38,500$0 M0.17%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC28,931$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC25,000$0 M0.11%<0.01%no changeJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust12,060$0 M0.05%<0.01%−48%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.13,514$0 M0.06%<0.01%−19%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC10,000$0 M0.04%0.01%−66%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC4,946$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.4,410$0 M0.02%<0.01%−86%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC3,587$0 M0.02%<0.01%+36%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC2,303$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation1,442$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation1,000$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust605$0 M<0.01%<0.01%−86%May 31, 2026
🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC588$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Avantis U.S. Equity FundAmerican Century ETF Trust188$0 M<0.01%<0.01%−33%May 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC117$0 M<0.01%<0.01%+6.4%Jul 31, 2026
🇺🇸 Avantis Responsible U.S. Equity ETFAmerican Century ETF Trust18$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 27 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at PetMed Express, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$44 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$44 K
open market only
Insiders on file
28
since
$1.0 M-$200 K$0Nov 2023: bought $451 K (3 trades), sold $0 (0 trades)Nov 23Aug 2024: bought $0 (0 trades), sold $2 K (1 trades)Sep 2024: bought $42 K (1 trades), sold $0 (0 trades)SepDec 2024: bought $728 K (13 trades), sold $0 (0 trades)Jan 2025: bought $364 K (3 trades), sold $0 (0 trades)Jan 25Feb 2025: bought $121 K (1 trades), sold $0 (0 trades)Mar 2025: bought $1.0 M (3 trades), sold $0 (0 trades)MarApr 2025: bought $0 (0 trades), sold $200 K (2 trades)May 2025: bought $126 K (2 trades), sold $0 (0 trades)MayJun 2025: bought $99 K (1 trades), sold $0 (0 trades)Jul 2025: bought $255 K (5 trades), sold $0 (0 trades)JulAug 2025: bought $700 K (2 trades), sold $0 (0 trades)Jun 2026: bought $44 K (1 trades), sold $0 (0 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
PetMed Express, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Douglas KrulikCAO and Interim CFOShares withheld for tax-2,435$1.190$3 K90,608Form 4
filed Jeffrey Allen WillardCEO and President, DirectorGrant or award+250,000——250,000Form 4
filed Douglas KrulikCAO and Interim CFOShares withheld for tax-3,246$1.530$5 K93,043Form 4
filed Tamar ElkelesDirectorGrant or award+49,923——49,923Form 4
filed Leslie C.g. CampbellInterim CEO and President, DirectorGrant or award+60,000——145,000Form 4
filed James LaCampDirectorGrant or award+55,555——90,421Form 4
filed Peter BatushanskyDirectorGrant or award+55,555——91,928Form 4
filed Justin L. MennenDirectorGrant or award+55,555——98,274Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: PetMed Express, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
829,531
3.9% of shares · 9.12 days to cover
Dividend per share, Q1 2025
$0.000
— on a year earlier
Buybacks, Q1 2021
$0M
Q4 2021
Shares sold short, last 24 reportsAll stocks →
PetMed Express, Inc. dividends per share by quarter
Dividend, quarterPer share
Q1 2025$0.000from the annual figure
Q4 2024$0.000
Q3 2024$0.000
Q2 2024$0.000
Q1 2024$0.000from the annual figure
Q4 2023$0.000
Q3 2023$0.300
Q2 2023$0.300
Q1 2023$0.300from the annual figure
Q4 2022$0.300
Q3 2022$0.300
Q2 2022$0.300
Q1 2022$0.300from the annual figure
Q4 2021$0.300
Q3 2021$0.300
Q2 2021$0.300
Q1 2021$0.280from the annual figure
Q4 2020$0.280
Q3 2020$0.280
Q2 2020$0.280
Q1 2020$0.270from the annual figure
Q4 2019$0.270
Q3 2019$0.270
Q2 2019$0.270
Q1 2019$0.270from the annual figure
Q4 2018$0.270
Q3 2018$0.270
Q2 2018$0.250
Q1 2018$0.250from the annual figure
Q4 2017$0.200
Q3 2017$0.200
Q2 2017$0.200
Q1 2017$0.190from the annual figure
Q4 2016$0.190
Q3 2016$0.190
Q2 2016$0.190
Q1 2016$0.180from the annual figure
Q4 2015$0.180
Q3 2015$0.180
Q2 2015$0.180
PetMed Express, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2021Q4 2021$0M
Q4 2020Q3 2021$0M
Q3 2020Q2 2021$0M
Q2 2020Q1 2021$0M
Q1 2020Q4 2020$0M
Q4 2019Q3 2020$0M
Q3 2019Q2 2020$0M
Q2 2019Q1 2020$11.5M
Q1 2013Q4 2012$0M
Q4 2012Q3 2012$0M
Q1 2012Q4 2011$0M
Q4 2011Q3 2011$1M
Q3 2011Q2 2011$9.1M
Q2 2011Q1 2011$13.6M
Q1 2011Q4 2011$7M
Q4 2010Q3 2011$1M

Trading halts

  • 2025-12-16 17:04 UTC, code LUDP, resumed 17:09 UTC

Fails to deliver

  • : 2,697 shares at $1.20
  • : 1,594 shares at $1.60
  • : 3,984 shares at $1.62
  • : 3 shares at $1.76
  • : 5 shares at $1.98

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

PetMed Express, Inc. scorecard#

Passes 4 of the 24 checks that could be worked out: strongest in valuation (2 of 5), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 15, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.9×Price to book 0.9× against Healthcare's median of 3.1×.
    • ✓Price to sales below its peers' median0.2×Price to sales 0.2× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-123.7%Free cash flow is -123.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-21.1%Revenue down 21.1% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-10.2%-10.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-10.2%-10.2% a year against Retail - Pharmacy's median of 0.4% (6 companies).
    • ✗Earnings per share grew in the newest year-2.74 vs -0.30Diluted EPS -2.74 in fiscal 2025 against -0.30 the year before (report's currency).
    • ✗Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against $24 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-32.8%-32.8% against Retail - Pharmacy's median of -2.4% (7 companies).
    • ✗Return on equity above 15%-100.5%-100.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-32.8%-32.8% in fiscal 2025 against 2.4% in 2022.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.84 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone0.16Z-score 0.16 (distress zone) for fiscal 2025.
  • Shareholder returns2 of 5
    • ✓Pays a dividendYesPaid dividends in fiscal 2025.
    • ✗Dividend per share raised five years in a row1 of 5Dividend per share raised in 1 of the five years to fiscal 2025.
    • –Dividends under 75% of net incomeNo payout ratio (a loss year).
    • ✓Share count up no more than 2% in a year1.6%Diluted shares up 1.6% in fiscal 2025.
    • ✗Dividends and buybacks above 3% of the market value0.1%Dividends and buybacks were 0.1% of the market value.
    • ✗Free cash flow covers dividends and buybacks-$33 MFree cash flow -$33 M against $0 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Retail - Pharmacy, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from PetMed Express, Inc.'s statements, beside the median of Retail - Pharmacy.

PetMed Express, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-32.8%-2.4%
Net margin-32.0%-1.4%
Return on equity-100.5%-49.7%
Revenue growth, 3 years a year-10.2%0.4%
Revenue growth-21.1%8.3%
Free cash flow margin-18.4%-0.3%

2of 8on the Piotroski tests of financial strength

  • Revenue fell 21.1% against the year before.
  • Net loss of $57 million, the 3th loss-making year in a row.
  • Free cash flow was negative: -$33 million.
  • Liabilities due within a year exceed current assets (current ratio 0.84).

PetMed Express, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

PetMed Express, Inc.: statements by fiscal year
PeriodTrendFY 2025to Mar 31, 2026FY 2024to Mar 31, 2025FY 2023to Mar 31, 2024FY 2022to Mar 31, 2023FY 2021to Mar 31, 2022FY 2020to Mar 31, 2021FY 2019to Mar 31, 2020FY 2018to Mar 31, 2019FY 2017to Mar 31, 2018FY 2016to Mar 31, 2017
Income statement
Revenue179227274r248r272r304r284283274249
Cost of revenue—158189r171r195219203188176170
Gross profit506985r77r77r84r81959879
General and administrative51395542r31r30r25252423
Operating expenses1097193r70r53r54r50494642
Operating income−59−1.5−8.26.1r24r31r31465237
Interest and finance income———2.10.30.31.71.90.70.1
Other non-operating income (expense)1.30.91.91.4r−0.1r0.4r2.92.91.70.4
Income before tax−57−0.6−6.37.4r24r31r34495438
Income tax−0.15.71.22.3r5.5r7.0r8.0111714
Net income attributable to shareholders−57−6.3−7.55.1r19r24r26383724
Earnings per share, basic-2.74-0.30-0.370.25r0.93r1.19r1.291.841.831.18
Earnings per share, diluted-2.74-0.30-0.370.25r0.92r1.19r1.291.841.821.17
Shares, weighted average (basic)21212020r20r2020202020
Shares, weighted average (diluted)21212020r20r2020202020
Dividends per share0.000.000.601.201.201.121.081.060.850.76
Balance sheet
Cash and cash equivalents2155551041111191041017859
Receivables1.92.33.31.71.92.63.82.52.31.8
Inventory141629———————
Other current assets6.45.36.34.74.94.53.51.40.91.0
Current assets447994130r15116112912610582
Property, plant and equipment26292726242525272930
Right-of-use (leased) assets0.51.01.40——————
Goodwill027270——————
Other intangible assets5.58.0110.9r0.90.90.90.90.90.9
Investments in associates——5.35.0——————
Non-current assets38707637r29r2626283031
Total assets81149170167r180r187155154135113
Accounts payable21243725284020161515
Current liabilities52637258r56r4524191818
Lease liabilities (non-current)0.00.51.00——————
Total liabilities52647358r56r4625201919
Retained earnings9.3677292r112r13412612210687
Shareholders' equity298597110r123r125r120r13511693
Total liabilities and equity81149170167r180r187155154135113
Shares outstanding212121r21r21202021r2121
Cash-flow statement
Depreciation and amortization9.47.07.13.52.7—————
Share-based compensation1.4−6.66.96.64.53.32.83.12.61.9
Cash from operating activities−284.74.328184039453747
Capital expenditure−4.6−5.1−4.5−5.3−1.8−2.4−2.3−0.6−0.7−11
Acquisitions, net of cash acquired00−3600—————
Cash from investing activities−4.6−5.1−41−10−1.8−2.4−2.3−0.6−0.7−11
Shares bought back————00−110——
Dividends paid−0.0−0.2−12−25−24−23−22−22−17−16
Cash from financing activities−0.3−0.2−12−25−24−23−33−22−17−16
Change in cash−33−0.6−49−7.0−7.6153.2231921
Report10-K10-K10-K10-K10-K10-K/A10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What PetMed Express, Inc. sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$179 M100%

Source: SEC annual report (XBRL data) · as of Mar 31, 2026

Executive pay at PetMed Express, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2026
$830 K
Jeffrey Allen Willard
Other top executives, average
$469 K
the CEO earned 1.8× this
$100 invested is now
$9
PetMed Express, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2026Jeffrey Allen Willard$830 K$813 K$469 K$9
2025Jeffrey Allen Willard$3.9 M$3.7 M$666 K$17
2024Mr. Mathew N. Hulett$534 K−$70 K$635 K$20

Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026

Events at PetMed Express, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling
  • Delisting noticeFiling
  • Financial statements withdrawnImpairmentFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Financial statements withdrawn 1 · Auditor changed 2 · Impairment 1 · Directors and officers 11 · Material agreement 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 7

PetMed Express, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Auditor changed8-K/A
Auditor changed8-K
Directors and officersMaterial agreementShareholder rights changed8-K
Delisting noticeResults announced8-K
Directors and officers8-K
Results announced8-K
Financial statements withdrawnImpairment8-K
Directors and officers8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Delisting notice8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreementShareholder rights changedBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 acquisitions, $36 M paid where reported

Businesses it acquired

Acquisitions by PetMed Express, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
PetCareRx2023—$36 M100%Annual report

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at PetMed Express, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $103 K a year.

Certified, FY2026
1
#1,849 among companies on value.today
Worker positions
1
Median wage offered
$103 K
a year, full-time
Applications filed
1
PetMed Express, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Software DeveloperSoftware Developers1$103 K

Where: Stamford, CT 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as PetMed Express, Inc.

How PetMed Express, Inc. compares in Retail - Pharmacy

  • Market cap$27 M · higher than 6% of 35
  • Revenue$179 M · higher than 5% of 38
  • Net margin-17.0% · higher than 0% of 36
  • Revenue growth-21.1% · higher than 10% of 11
  • Price / sales0.2× · lower than 96% of 25
  • Price / book0.9× · lower than 91% of 23
  • FCF yield-123.7% · higher than 0% of 5

Peer comparison · Retail - Pharmacy

CompanyMarket capP/ENet marginRev. growth
PetMed Express, Inc.🇺🇸$27 M—-17.0%-21.1%
Tsuruha Holdings Inc.🇯🇵$6.9 B23.8×2.9%—
Alibaba Health Information Technology Limited🇭🇰$6.7 B24.0×5.7%—
Matsumotokiyoshi Holdings🇯🇵$6.2 B16.5×5.0%—
Yifeng Pharmacy Chain Co., Ltd.🇨🇳$4.3 B17.8×6.9%—
Raia Drogasil S.A.🇧🇷$4.1 B16.8×2.9%—
Selçuk Ecza Deposu Ticaret Ve Sanayi A.S.🇹🇷$3.7 B72.7×3.5%—
Sugi Holdings Co., Ltd.🇯🇵$3.3 B23.6×3.1%—
Cosmos Pharmaceutical Corporation🇯🇵$3.3 B19.5×3.1%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 15, 2026
Annual results:
For year ending March-2026
Balance sheet:
As of March-2026
Employees:
As on 2022
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, Wikimedia Commons, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at PetMed Express, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show PetMed Express, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about PetMed Express, Inc.? Suggest a correction